Plain-English translation of NCT05092451 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called CAR.70/IL15-transduced cord blood-derived NK cells for people with blood cancers that have come back or stopped responding to standard treatments. The medication uses immune cells from donated umbilical cord blood that have been specially engineered in the laboratory to recognize and fight cancer cells. You would receive chemotherapy first to prepare your body, then receive an infusion of these engineered cells.
Many patients with blood cancers like lymphoma, leukemia, and myeloma don't respond well to standard treatments or experience a relapse. This medication represents a new approach using naturally powerful immune cells that have been enhanced to target cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would first receive chemotherapy medications ( and fludarabine) over several days to prepare your immune system. After a short recovery period, you would receive a single infusion of the engineered immune cells. You would then be monitored closely with blood tests and imaging scans to see how well the treatment works and to watch for any side effects. You would also need to commit to long-term follow-up visits and testing to track how the cells persist in your body and how your cancer responds.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States